Berg_Logo Site navigation ABOUT US RESEARCH & DEVELOPMENT PARTNERS MEDIA CAREERS CONTACT Search BACK TO BIOLOGY™ BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology®, our goal is to map disease and revolutionize treatments for patients around the world. OUR VISION By harnessing the power of AI, coupled with patient biology, we aim to accelerate clinical identification and pursuit of promising therapeutic targets to treat disease. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. By going ‘Back to Biology™’, we believe we can drive healthcare forward. OUR FOCUS ONCOLOGY NEUROLOGY RARE DISEASE PROGRESS, FOR PEOPLE™ At BERG, we believe in making Progress, for People™. People not only inspire the work we do, but are at the center of our R&D. BERG harnesses the true potential of modern technology to gather trillions of data points to map diseases in unprecedented detail. This revolutionary approach aims to bring new treatments and new hope to the millions of patients and caregivers in need of novel treatment options. BERG IN THE NEWS SEPTEMBER 15, 2021 Exclusive: Berg Health, Microsoft partner on cloud-based bioanalysis tool SEPTEMBER 7, 2021 Biomarker panel to elevate prostate cancer diagnostics: Berg APRIL 1, 2021 Berg taps into supercomputer to battle COVID-19 variants OCTOBER 6, 2020 Healthcare Leaders Pioneer A New Collaboration Model To Transform The Future Of Drug Development SEPTEMBER 28, 2020 Berg Fuels Study of African-American COVID-19 Patients JUNE 18, 2020 Energy Department Uses Supercomputers to Tackle COVID-19 MAY 6, 2020 Boehringer Ingelheim adds second AI partner in a month MARCH 5, 2020 Transforming Drug Discovery through Artificial Intelligence. FEBRUARY 15, 2020 The December 2019 issue of Nature magazine describes the unique potential of the BERG platform in combining patient biology & artificial intelligence for drug and clinical development, highlights its use in the development of BPM 31510 in oncology. VIEW ALL NEWS Berg_Logo ABOUT US Leadership Team Founders Board of Directors Scientific Advisory Board RESEARCH & DEVELOPMENT Healthcare Professionals Our Pipeline Publications Patients and Caregivers Our Science Epidermolysis Bullosa (EB) Chemotherapy-Induced-Alopecia (CIA) Pancreatic Cancer Expanded Access and Compassionate Use Medical Resources Clinical Trials PARTNERS Pharmaceutical Healthcare Academic Government MEDIA News Features Press Releases Events Media Kit Clinical Trials CAREERS Join Our Team CONTACT Investor contact Media contact Partner contact Connect with us Headquarters and Innovation Center 500 Old Connecticut Path Framingham, MA 01701 Tel: (617) 588-0083 Email: Info@Berghealth.com © 2021 BERG LLCLEGAL Visit BERG on LinkedIn Visit BERG on Twitter Visit BERG on Facebook Visit the BERG YouTube channel